Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Breast Cancer

Free Subscription 14.09.2026 2 AJR Am J Roentgenol 2 Am J Clin Oncol 1 Ann Oncol 3 Ann Surg Oncol 1 BMC Cancer 2 Breast Cancer 1 Breast Cancer (Auckl) 2 Breast Cancer (Dove Med Press) 1 Breast Cancer Res 4 Breast Cancer Res Treat 1 Cancer 1 Cancer Epidemiol Biomarkers Prev 2 Cancer Lett 1 Carcinogenesis 15 Clin Breast Cancer 2 Clin Cancer Res 2 Eur J Cancer 1 Eur J Surg Oncol 2 Eur Radiol 2 Histopathology 2 Int J Cancer 1 J Biol Chem 2 J Clin Oncol 5 J Natl Cancer Inst 1 J Nucl Med 1 J Pathol 1 Nat Rev Cancer 2 Nature 1 PLoS Comput Biol 2 PLoS One 1 Pol J Radiol 1 Radiol Artif Intell 1 Radiol Imaging Cancer 1 Radiologia (Engl Ed) 1 Science 1 Semin Oncol

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

AJR Am J Roentgenol

1. DIBBLE EH
   Specimen [(18)F]FDG PET/CT for Assessing Intraoperative Margins in Early-Stage Breast Cancer: A Promising Emerging Technology.
   AJR Am J Roentgenol. 2026 Sep 9. doi: 10.2214/AJR.26.35861.
   PubMed        
   
   
2. BAIRD GL
   Predicting 5-Year Breast Cancer Risk From Longitudinal Digital Breast Tomosynthesis: What to Tell Patients.
   AJR Am J Roentgenol. 2026 Sep 9. doi: 10.2214/AJR.26.35782.
   PubMed        
   
   

   
   Am J Clin Oncol

3. TOLENTINO LG, Khaustova M, Alrwaitey RZ, Chintala AS, et al
   Efficacy and Safety of Sacituzumab Govitecan for Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials (RCTs).
   Am J Clin Oncol. 2026 Sep 9. doi: 10.1097/COC.0000000000001365.
   PubMed         Abstract available
   
   
4. KONSKI AA, Chung Y, Liu CM, Rula EY, et al
   Ultra-Hypofractionated Radiotherapy in Breast Cancer Before and After COVID-19.
   Am J Clin Oncol. 2026 Sep 9. doi: 10.1097/COC.0000000000001373.
   PubMed         Abstract available
   
   

   
   Ann Oncol

5. ZHANG J, Meng Y, Du Y, Sun T, et al
   Safety and antitumor activity of the first-in-class EGFR-HER3 bispecific antibody-drug conjugate iza-bren (BL-B01D1) in patients with pretreated locally advanced or metastatic breast cancer: a phase 1b study.
   Ann Oncol. 2026 Sep 11:S0923-7534(26)06634-2. doi: 10.1016/j.annonc.2026.
   PubMed         Abstract available
   
   

   
   Ann Surg Oncol

6. TSENG J, Dimitroff K, Sauder CAM, Chien AJ, et al
   Correction: ASO Visual Abstract: Surgical Management of Young Women with High-Risk Breast Cancer Receiving Neoadjuvant Systemic Therapy in the I-SPY2 Trial.
   Ann Surg Oncol. 2026 Sep 5. doi: 10.1245/s10434-026-20527.
   PubMed        
   
   
7. AMBURN T, Joseph KA
   ASO Author Reflections: Preferred Language as a Social Determinant of Health in Breast Cancer Care.
   Ann Surg Oncol. 2026 Sep 8. doi: 10.1245/s10434-026-20540.
   PubMed        
   
   
8. NUNEZ O, Govind V, Wolde T, Heath R, et al
   ASO Visual Abstract: Variant of Uncertain Significance is Associated with Increased Bilateral Mastectomy in Lumpectomy-Eligible Breast Cancer Patients.
   Ann Surg Oncol. 2026 Sep 8. doi: 10.1245/s10434-026-20518.
   PubMed        
   
   

   
   BMC Cancer

9. MEISAMY S, Brattain K, Shao Q, Steinberger D, et al
   Measurement of metabolic activity by telemetric temperature sensing after immunotherapy and chemotherapy on three different mouse tumor models.
   BMC Cancer. 2026;26:1087.
   PubMed         Abstract available
   
   

   
   Breast Cancer

10. GEBHART P, Heinzl F, Kahl C, Bari A, et al
    Pathologic complete response and survival according to germline BRCA1/2 status in triple-negative breast cancer.
    Breast Cancer. 2026 Sep 10. doi: 10.1007/s12282-026-01914.
    PubMed         Abstract available
    
    
11. MASUDA H, Konishi T, Onishi M, Ito A, et al
    Correction: Initial activities and prospects of MIRAY1: a youth-driven, society-endorsed initiative to cultivate future breast cancer physicians.
    Breast Cancer. 2026 Sep 6. doi: 10.1007/s12282-026-01906.
    PubMed        
    
    

    
    Breast Cancer (Auckl)

12. OBEAGU EI, Okafor CJ
    Circulating Tumor DNA in Breast Cancer: A Liquid Biopsy Revolution for Non-Invasive Genomic Profiling and Clinical Decision-Making.
    Breast Cancer (Auckl). 2026;20:11782234261485831.
    PubMed         Abstract available
    
    

    
    Breast Cancer (Dove Med Press)

13. WANG H, Tian R, Li J, Liu W, et al
    Nanomedicine-Based Strategies Targeting Macrophage Polarization in Breast Cancer Bone Metastasis: An Updated Review.
    Breast Cancer (Dove Med Press). 2026;18:588449.
    PubMed         Abstract available
    
    
14. ZHANG S, Zhao J, Zhao Y, Zhi Z, et al
    Prognostic Significance of the Triglyceride-to-High-Density Lipoprotein Cholesterol Ratio (TG/HDL-C) in Breast Cancer Patients: A Real-World Retrospective Study.
    Breast Cancer (Dove Med Press). 2026;18:619932.
    PubMed         Abstract available
    
    

    
    Breast Cancer Res

15. SHEPHERD J, Bertrand K, Strand F, Vachon C, et al
    International breast density and cancer risk assessment workshop: advances, challenges, and emerging solutions, a summary from the 11th IBDW, Kaua'i 2025.
    Breast Cancer Res. 2026;28.
    PubMed         Abstract available
    
    

    
    Breast Cancer Res Treat

16. LIU J, Ding L, Wang J, Chen T, et al
    Exploring trop-2-directed ADCs monotherapy and combination therapy in pretreated mTNBC: a real-world study.
    Breast Cancer Res Treat. 2026;219:10.
    PubMed         Abstract available
    
    
17. KROLL MR, Schroeder MC, Neuner JM, Viyyuri BR, et al
    Anthracycline-containing versus anthracycline-free carboplatin-based regimens in early-stage triple-negative breast cancer: real-world outcomes.
    Breast Cancer Res Treat. 2026;219:7.
    PubMed         Abstract available
    
    
18. MEISEL JL, Chen C, Kris A, Ru M, et al
    Real-world treatment patterns and clinical outcomes in patients with emerging estrogen receptor 1 (ESR1)-mutated ER+ metastatic breast cancer in the U.S., 2018-2024.
    Breast Cancer Res Treat. 2026;219:9.
    PubMed         Abstract available
    
    
19. MEISEL J, Pham T, Chen C, Kris A, et al
    Real-world estrogen receptor alpha 1 (ESR1) testing patterns and results for ER+/HER2- metastatic breast cancer in the United States, 2018-2024.
    Breast Cancer Res Treat. 2026;219:8.
    PubMed         Abstract available
    
    

    
    Cancer

20. MAZZITELLI N, Star J, Meggett K, Han X, et al
    Prevalence of breast, cervical, and colorectal cancer screening among adults according to disability type and difficulty level, United States, 2021 and 2023.
    Cancer. 2026;132:e70557.
    PubMed         Abstract available
    
    

    
    Cancer Epidemiol Biomarkers Prev

21. PETRELLI F, Ghidini A, Borgonovo K, Ghilardi M, et al
    Sunlight Exposure and Breast Cancer Risk: A Systematic Review and Meta-analysis.
    Cancer Epidemiol Biomarkers Prev. 2026.
    PubMed         Abstract available
    
    

    
    Cancer Lett

22. WANG H, Zhang Y, Liu D, Liu C, et al
    A Copper(I)-Azurin complex suppresses p53-mediated glycolysis to sensitize breast cancer to cuproptosis with MRI monitoring.
    Cancer Lett. 2026;660:218831.
    PubMed         Abstract available
    
    
23. JI P, Wu HL, He LH, Wang H, et al
    Integrated analysis reveals the impact of obesity on triple-negative breast cancer.
    Cancer Lett. 2026;660:218833.
    PubMed         Abstract available
    
    

    
    Carcinogenesis

24. WU Z, Wang S, Yang Q, Gong Y, et al
    PHB2 Promotes Glycolytic Reprogramming in Triple-Negative Breast Cancer Through FOXM1-Dependent Activation of LDHB.
    Carcinogenesis. 2026 Sep 8:bgag066. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    Clin Breast Cancer

25. CARGILL KR, Elmore LR, Goktepe B, Bayley EM, et al
    Evaluation of Absorbable Hemostatic Powder on Postoperative Outcomes in Patients Undergoing Mastectomy.
    Clin Breast Cancer. 2026;26:121-126.
    PubMed         Abstract available
    
    
26. BRIERLEY-GREEN E, Duggirala N, McCann KE, Callahan R, et al
    Novel Endocrine Therapies: Current Status and Future Directions.
    Clin Breast Cancer. 2026;26:127-136.
    PubMed         Abstract available
    
    
27. COOPER JT, Hollingsworth A, Moore RD, Croft C, et al
    Cost-effectiveness of Biennial Breast Screening in Women With Dense Breasts: Exploratory Analysis of Pathways Incorporating an Emerging Blood RNA Test.
    Clin Breast Cancer. 2026;26:171-178.
    PubMed         Abstract available
    
    
28. HUANG K, Gabriel E
    Overall Survival After Sentinel Lymph Node Biopsy Versus Axillary Lymph Node Dissection in Patients With Three Recorded Positive Nodes: A National Cancer Database Analysis.
    Clin Breast Cancer. 2026;26:186-192.
    PubMed         Abstract available
    
    
29. BRODIE A, Gaber A, Kaushik M, Krupa J, et al
    Association of Therapeutic Mammoplasty and Radiotherapy Side-effects.
    Clin Breast Cancer. 2026;26:199-203.
    PubMed         Abstract available
    
    
30. SHENG X, Yin H, Zhang X, Ma L, et al
    A Multicenter Retrospective Study on Screening Patients Eligible for Exemption From Axillary Surgery Based on the Pathological Remission of the Breast After Neoadjuvant Therapy.
    Clin Breast Cancer. 2026;26:204-210.
    PubMed         Abstract available
    
    
31. EL ANNAN R, El-Jammal M, Zeidan YH
    Axillary Surgery in Sentinel Node-Positive Breast Cancer After Neoadjuvant Therapy: A Systematic Review and Meta-analysis.
    Clin Breast Cancer. 2026;26:18-25.
    PubMed         Abstract available
    
    
32. TRIKHA M, Rath S, Ventrapati P, Bhargava P, et al
    Self-Reported Compliance With Adjuvant Endocrine Therapy in Young Women With Hormone Receptor-Positive Early Breast Cancer: A Real-World Study from a Tertiary Cancer Center in India.
    Clin Breast Cancer. 2026;26:26-32.
    PubMed         Abstract available
    
    
33. LIM J, Gomez C, Haydon M, Singh H, et al
    Synchronous Contralateral Breast Cancer Detected at Elective Bilateral Mastectomy: Incidence, Predictors, and Biomarker Concordance in the National Cancer Database.
    Clin Breast Cancer. 2026;26:33-39.
    PubMed         Abstract available
    
    
34. FUJIMOTO A, Ichinose Y, Matsuura K, Mikami E, et al
    Neutrophil-to-Lymphocyte Ratio Predicts Pathological Complete Response in Triple-Negative Breast Cancer Treated With Neoadjuvant Pembrolizumab Plus Chemotherapy.
    Clin Breast Cancer. 2026;26:52-57.
    PubMed         Abstract available
    
    
35. HUANG J, Zhang S, Zhang D, Wu L, et al
    Cancer-Associated Fibroblasts-Derived Exosomal METTL3 Drives Breast Cancer Malignancy by Eliciting PABPN1 m6A Modification.
    Clin Breast Cancer. 2026;26:40-51.
    PubMed         Abstract available
    
    
36. SILVA TAD, Fernandes EV, Bocchi M, Neto FSL, et al
    Epigenetic Remodeling Through GSK343-induced EZH2 Inhibition Alters SMYD2/SMYD3 Expression and Promotes Antitumor Effects.
    Clin Breast Cancer. 2026;26:101-106.
    PubMed         Abstract available
    
    
37. KONG V, Jiang J, Niederegger T, Schaschinger T, et al
    Finding the Sweet Spot? Differential Diabetes Risks in Autologous Breast Reconstruction.
    Clin Breast Cancer. 2026;26:66-74.
    PubMed         Abstract available
    
    
38. CRIPE L, Sweatt I, Michael G, Byerly S, et al
    Feasibility of Same Day Mastectomy Discharge in a Safety Net Hospital in Memphis, TN.
    Clin Breast Cancer. 2026;26:62-65.
    PubMed         Abstract available
    
    
39. GUNAY A, Guler S
    Determination of Body Perceptions and Preferences for Breast Reconstruction in Mastectomy Patients.
    Clin Breast Cancer. 2026;26:44-52.
    PubMed         Abstract available
    
    

    
    Clin Cancer Res

40. ZHANG J, Zhu J, Yang Y, Song D, et al
    Neoadjuvant Pertuzumab Biosimilar HLX11 Versus Reference Pertuzumab for Early-stage or Locally Advanced Breast Cancer: A phase 3 Equivalence Trial.
    Clin Cancer Res. 2026 Sep 9. doi: 10.1158/1078-0432.CCR-26-1604.
    PubMed         Abstract available
    
    
41. MAI N, Nag S, Liu B, Chen W, et al
    ERBB2 Activating Mutations Promote Enhanced Internalization and Activity of Trastuzumab Deruxtecan in HER2-non-amplified Metastatic Breast Cancer.
    Clin Cancer Res. 2026 Sep 9. doi: 10.1158/1078-0432.CCR-26-0198.
    PubMed         Abstract available
    
    

    
    Eur J Cancer

42. CONFORTI F, Canzian J, Tinterri B, Pala L, et al
    Decluttering chemotherapy agents for HER2+early breast cancer: Do we still need carboplatin?
    Eur J Cancer. 2026;247:117015.
    PubMed         Abstract available
    
    
43. TARANTINO P, Li T, Pare Brunet L, Sanfeliu E, et al
    Association of immune and proliferation gene signatures and stromal tumor-infiltrating lymphocytes with clinical outcomes in patients with stage I triple-negative breast cancer.
    Eur J Cancer. 2026;247:117020.
    PubMed         Abstract available
    
    

    
    Eur J Surg Oncol

44. XU W, Wu Y, Yang Y, Zhao X, et al
    Exploring heterogeneity in survival benefit of neoadjuvant therapy for triple-negative breast cancer using causal survival forests.
    Eur J Surg Oncol. 2026;52:112108.
    PubMed         Abstract available
    
    

    
    Eur Radiol

45. ALTUNDAG K
    Letter to the Editor: Clinical implications of automated breast ultrasound in preoperative breast cancer staging.
    Eur Radiol. 2026 Sep 8. doi: 10.1007/s00330-026-12853.
    PubMed        
    
    
46. CHOI JS, Ko EY
    Reply to the Letter to the Editor: Clinical implications of automated breast ultrasound in preoperative breast cancer staging.
    Eur Radiol. 2026 Sep 8. doi: 10.1007/s00330-026-12852.
    PubMed        
    
    

    
    Histopathology

47. CHENG A, Barnes P, Rayson D, Liwski C, et al
    Pathological assessment of tumour beds in breast excisions post-neoadjuvant therapy: a retrospective cohort study.
    Histopathology. 2026;89:650-657.
    PubMed         Abstract available
    
    
48. YENI YILDIRIM S, Selenica P, Gazzo A, Djerroudi L, et al
    Landscape of genetic alterations affecting cancer genes in primary and advanced malignant phyllodes tumours.
    Histopathology. 2026;89:603-613.
    PubMed         Abstract available
    
    

    
    Int J Cancer

49. ALTENDORFER S, Walker SJ, Daub CO
    Impact of Single-Cell RNA Reference Selection for the Deconvolution of Breast Cancer Spatial Transcriptomics Datasets.
    Int J Cancer. 2026 Sep 8. doi: 10.1002/ijc.70733.
    PubMed         Abstract available
    
    
50. SHAN Y, Rothbard SM, Rosenberg L, Palmer JR, et al
    Cardiometabolic Health and Risk of Breast Cancer Subtypes Among US Black Women.
    Int J Cancer. 2026 Sep 7. doi: 10.1002/ijc.70734.
    PubMed         Abstract available
    
    

    
    J Biol Chem

51. DAW JN, Moly PK, Chung S, Young S, et al
    Nitric oxide dependent metabolic and genetic dysregulation in metastatic triple-negative breast cancer.
    J Biol Chem. 2026 Sep 8:113526. doi: 10.1016/j.jbc.2026.113526.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

52. ZHANG J, Ouyang Q, Zhang Q, Li H, et al
    Trastuzumab Botidotin Versus Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: A Phase III, Open-Label, Randomized Controlled Trial.
    J Clin Oncol. 2026 Sep 11:JCO2600602. doi: 10.1200/JCO-26-00602.
    PubMed         Abstract available
    
    
53. KLEEMAN SO, Stearns V
    Risk-Adapted Optimization of Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2-Positive Early-Stage Breast Cancer.
    J Clin Oncol. 2026 Sep 9:JCO2601423. doi: 10.1200/JCO-26-01423.
    PubMed         Abstract available
    
    

    
    J Natl Cancer Inst

54. SRINIVASAN A, Wang J, Matt G, Mills LJ, et al
    Integrating genetic predictors into subsequent breast cancer risk prediction in survivors of childhood cancer.
    J Natl Cancer Inst. 2026 Sep 9:djag306. doi: 10.1093.
    PubMed         Abstract available
    
    
55. 
    Correction: TP53 Status as a Determinant of Pro- vs Anti-Tumorigenic Effects of Estrogen Receptor-Beta in Breast Cancer.
    J Natl Cancer Inst. 2026 Sep 10:djag277. doi: 10.1093.
    PubMed        
    
    
56. COSTA DE ALMEIDA LF, Cappellaro AP, Noronha MM, Diniz da Conceicao L, et al
    Treatment Effect Discrepancy Between PFS and OS in Antibody-Drug Conjugate Trials for Metastatic Breast Cancer: A Meta-Epidemiologic Analysis.
    J Natl Cancer Inst. 2026 Sep 10:djag324. doi: 10.1093.
    PubMed         Abstract available
    
    
57. NASH S, Hammarstrom M, Thorngen JO, Winqvist O, et al
    Endocrine Biomarker Changes in a Randomised Low-Dose Tamoxifen Trial for Breast Cancer Prevention.
    J Natl Cancer Inst. 2026 Sep 10:djag321. doi: 10.1093.
    PubMed         Abstract available
    
    
58. SERRANO D, Rizzo R, Johansson H, Macis D, et al
    SHBG as a breast cancer risk biomarker in premenopausal women? Results from an individual patient's pooled analysis and a meta-analysis.
    J Natl Cancer Inst. 2026 Sep 11:djag318. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Nucl Med

59. NDLOVU H, Lawal IO, Moholisa RR, Kabunda J, et al
    Lesion Detection and Uptake Patterns of [(18)F]F-ATD001 PET/CT and [(18)F]FDG PET/CT in Triple-Negative Breast Cancer.
    J Nucl Med. 2026 Sep 10:jnumed.125.271973. doi: 10.2967/jnumed.125.271973.
    PubMed         Abstract available
    
    

    
    J Pathol

60. GAO Y, Yao F, Pang J, Sun T, et al
    Differential FGFR1 copy number status displays unique tumour immune microenvironment in triple-negative breast cancer.
    J Pathol. 2026 Sep 9. doi: 10.1002/path.70121.
    PubMed         Abstract available
    
    

    
    Nat Rev Cancer

61. MUTEBI M
    Making breast cancer innovation deliver for every woman.
    Nat Rev Cancer. 2026 Sep 11. doi: 10.1038/s41568-026-00982.
    PubMed        
    
    

    
    Nature

62. GUARDUCCI C, Malorni L
    The secret life of a cell-cycle gatekeeper of breast cancer.
    Nature. 2026;657:357-358.
    PubMed        
    
    
63. NADDAF M
    AI model predicts which breast-cancer drugs work best.
    Nature. 2026 Sep 9. doi: 10.1038/d41586-026-02845.
    PubMed        
    
    

    
    PLoS Comput Biol

64. HUANG ZH, Xu Z, Hu P
    Spatially guided translation from histology images to transcriptomic profiles using foundation model-driven contrastive learning.
    PLoS Comput Biol. 2026;22:e1014762.
    PubMed         Abstract available
    
    

    
    PLoS One

65. WON SH, Kim YA, Suh SY, Im JH, et al
    Preferences and reasons for clothing colors in women patients and survivors of breast cancer in Korea.
    PLoS One. 2026;21:e0357499.
    PubMed         Abstract available
    
    
66. VAZQUEZ-ROLDAN M, Ortiz-Ortiz KJ, Millan-Perez LI, Gierbolini-Bermudez A, et al
    The impact of anxiety and affective disorders on breast cancer screening in women in Puerto Rico.
    PLoS One. 2026;21:e0357375.
    PubMed         Abstract available
    
    

    
    Pol J Radiol

67. JOHNSON A, Sarawagi R, Malik R
    Utility of signal enhancement ratio on DCE-MRI for detection of residual breast cancer following surgery or neoadjuvant chemotherapy - a pilot study.
    Pol J Radiol. 2026;91:e361-e368.
    PubMed         Abstract available
    
    

    
    Radiol Artif Intell

68. LU C, Wang X, Zhang T, Liang X, et al
    A Deep Learning Model to Predict Breast Cancer Recurrence Using Longitudinal Mammograms and Clinical Data.
    Radiol Artif Intell. 2026 Sep 9:e250941. doi: 10.1148/ryai.250941.
    PubMed         Abstract available
    
    

    
    Radiol Imaging Cancer

69. YADAV P
    Diffusion-weighted Imaging and ADC Mapping for Early Prediction of Pathologic Complete Response in Breast Cancer.
    Radiol Imaging Cancer. 2026;8:e260464.
    PubMed        
    
    

    
    Radiologia (Engl Ed)

70. MARISCAL MARTINEZ A, Peris Alva H, Salazar Gomez AP, Rodriguez Martinez P, et al
    Use of contrast-enhanced mammography for the diagnosis and staging of invasive lobular breast cancer.
    Radiologia (Engl Ed). 2026;68:501725.
    PubMed         Abstract available
    
    

    
    Science

71. CURTIN MC, Jackson AE, Lee MD, Brown EA, et al
    Lean adipocyte oxylipin signaling restrains breast cancer through ferroptosis.
    Science. 2026;393:eaea4287.
    PubMed         Abstract available
    
    

    
    Semin Oncol

72. ALAHMED A, Al-Hanaktah M, Alroud E, Salah B, et al
    Uncovering an uncommon diagnosis: Encapsulated papillary carcinoma of the male breast in a Jordanian patient-A case report.
    Semin Oncol. 2026;53:152538.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum